Dexmedetomidine for Non-invasive Ventilation After Chest Trauma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Crossover randomized controlled double blinded trial :
- The primary endpoint is the duration of Non Invasive Ventilation (NIV) session (minutes)
with dexmedetomidine (DEX) or placebo.
- Secondary endpoints will be the sedation level as assessed by the Richmond Agitation
Sedation Scale (RASS), the number of interventions to allow the completion of NIV
session, the pain intensity level as assessed by visual analogue scale, the morphine and
ketamine consumption during NIV sessions, the comparison of blood gas measurements
before and after NIV sessions, the reproducibility of NIV cycles. The side effects of
DEX will be notified.